Ep. 109 - What's Next for Novartis? Plus: AACR, Merck KGaA
BioCentury This Week
00:00
Is Onchology Really Retaining?
Onchology no longer constitutes one of the two major divisions within their innovative medicines unit. I think they'll be focused more whilst ilbing o carty in the next yes. Another thing i thought was interesting, or iinteresting, is the re hiring of sheram aradia as president of global drug development and c m o. He comes from a dicerna, which is an rna company. And notably, nevadus has not on aladin rana. We have two women on the 11 percen nevadas executive team. But we're batting at about 20 % there.
Transcript
Play full episode
